Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21684954 | 0.79 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2CDK2 | |
| SCHEMBL5145883 | 0.79 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2CDK2ALDH1A1HPGD | |
| SCHEMBL135689 | 0.79 | CDK2 (0.52) | CSNK2A1CSNK2A2CDK2ALDH1A1HPGD | |
| SCHEMBL16147073 | 0.79 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2 | |
| SCHEMBL15744214 | 0.79 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2CDK2 | |
| SCHEMBL842437 | 0.79 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2CDK2KDM4EALDH1A1 | |
| SCHEMBL2352412 | 0.79 | CSNK2A1 (0.41) | CSNK2A1CSNK2A2KDM4EALDH1A1HPGD | |
| SCHEMBL16146457 | 0.79 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2LMNAMEN1KMT2A | |
| SCHEMBL5935894 | 0.79 | CSNK2A1 (0.41) | CSNK2A1CSNK2A2CDK2KDM4EDYRK1A | |
| SCHEMBL16146987 | 0.76 | XDH (0.38) | CSNK2A1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| EP-2415776-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| EP-1292313-A2 | METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2003-03-19 | — | — | EP | disclosed |
| EP-1284720-A2 | METHOD OF TREATING HEPATITIS DELTA VIRAL INFECTION | Georgetown University (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020160980-A1 | Method of treating hepatitis delta virus infection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC | 2002-10-31 | — | — | US | disclosed |
| US-6444652-B1 | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B | NOVIRIO PHARMACEUTICALS LIMITED (CY) | 2002-09-03 | — | — | US | disclosed |
| US-6395716-B1 | Antivirals such as telbivudine | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2002-05-28 | — | — | US | disclosed |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | NOVARTIS AG (CH) | 2002-03-21 | — | — | US | disclosed |
| WO-2001091737-A2 | METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001072294-A2 | METHOD OF TREATING HEPATITIS DELTA VIRAL INFECTION | GEORGETOWN UNIVERSITY (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1104436-A2 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B VIRUS | Idenix (Cayman) Limited (KY) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009531-A2 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | CSNK2A1 2190/4885CSNK2A2 1826/4885CDK2 1302/4885 |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | DCTD, DUT, DPYD | CSNK2A1 3523/4885CSNK2A2 3214/4885CDK2 2921/4885 |
| US-20020160980-A1 | Method of treating hepatitis delta virus infection | NSUN3, METTL3, METAP1 | CSNK2A1 3161/4885CSNK2A2 3721/4885CDK2 2633/4885 |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | CSNK2A1 2190/4885CSNK2A2 1826/4885CDK2 1302/4885 |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | CSNK2A1 2190/4885CSNK2A2 1826/4885CDK2 1302/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | CSNK2A1 2190/4885CSNK2A2 1826/4885CDK2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.